Clinical Trials Browser

Expanded_access × Recurrence × 1 year × Clear all

NCT05619367 2025-12-23

A Compassionate Use (CU) Program of Odronextamab

Lymphoma, Follicular, Recurrence, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT05503550 2025-12-16

Pre-Approval Access Single Patient Request for Talquetamab in Relapsed or Refractory Multiple Myeloma

No longer available

Multiple Myeloma, Recurrence

NCT05757973 2025-12-09

Pre-Approval Access Program for Talquetamab in Relapsed or Refractory Multiple Myeloma

Approved for marketing

Multiple Myeloma, Recurrence

NCT05164250 2025-11-10

Compassionate Use (CU) of REGN5458 for Patients With Relapsed or Refractory Multiple Myeloma (MM)

Approved for marketing

Multiple Myeloma, Recurrence

NCT05918913 2025-09-05

Expanded Access Program for Revumenib

No longer available

Other hematologic neoplasm

Leukemia, Recurrence

NCT04008524 2025-08-06

A Clinical Study of CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies

Other hematologic neoplasm

Recurrence, Hematologic Neoplasms

NCT06872489 2025-07-23

Expanded Access Protocol for the Use of SL-28 in the Treatment of Advanced Solid Tumors

CNSGastrointestinalHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Neuroblastoma, Pancreatic Neoplasms, Recurrence

NCT01370330 2025-07-22

131I-Labeled MIBG for Refractory Neuroblastoma: A Compassionate Use Protocol

Neoplasms, Neuroblastoma, Recurrence

NCT05463939 2025-06-15

Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Multiple Myeloma Patients

Approved for marketing

Multiple Myeloma, Recurrence